Advanced in Felty Syndrome

Dr. Jan E. Duus

Hematology Oncology | Hematology | Oncology
75 Beekman St, 
Plattsburgh, NY 
Advanced in Felty Syndrome
75 Beekman St, 
Plattsburgh, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jan Duus is a Hematologist Oncology specialist and a Hematologist in Plattsburgh, New York. Dr. Duus is rated as an Advanced provider by MediFind in the treatment of Felty Syndrome. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), Non-Hodgkin Lymphoma, and Bone Marrow Aspiration.

His clinical research consists of participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO

Locations

75 Beekman St, Plattsburgh, NY 12901

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Lenalidomide
Study Phase: Phase 3
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy - The C-TRACT Trial
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy - The C-TRACT Trial
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2025
Intervention Type: Device
Study Phase: Not Applicable
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
View 5 Less Clinical Trials
Similar Doctors
Experienced in Felty Syndrome
Dr. Myrna A. Sanchez-Latreille
Oncology | Palliative Medicine | Hematology Oncology
Experienced in Felty Syndrome
Dr. Myrna A. Sanchez-Latreille
Oncology | Palliative Medicine | Hematology Oncology

Alice Hyde Medical Center

133 Park St, 
Malone, NY 
 (41.7 miles away)
518-481-2545
Languages Spoken:
English
See accepted insurances

Myrna Sanchez-Latreille is an Oncologist and a Palliative Medicine provider in Malone, New York. Dr. Sanchez-Latreille is rated as an Advanced provider by MediFind in the treatment of Felty Syndrome. Her top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Pleuropulmonary Blastoma, and Anemia.

Experienced in Felty Syndrome
Dr. Vanessa F. Fiorini-Furtado
Oncology | Hematology
Experienced in Felty Syndrome
Dr. Vanessa F. Fiorini-Furtado
Oncology | Hematology

Elizabethtown Community Hospital

75 Park St, 
Elizabethtown, NY 
 (34.0 miles away)
518-673-6377
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Vanessa Fiorini-Furtado is an Oncologist and a Hematologist in Elizabethtown, New York. Dr. Fiorini-Furtado is rated as an Advanced provider by MediFind in the treatment of Felty Syndrome. Her top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Paget Disease of the Breast, Breast Cancer, and Angiosarcoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Duus's expertise for a condition
ConditionClose
    View All 12 Distinguished Conditions
    View All 33 Advanced Conditions
    View All 107 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile